Compass Pathways' Psilocybin Pill COMP360 Nears Market Launch

• Compass Pathways aims to market its psilocybin pill COMP360 for treatment-resistant depression.
• CEO Kabir Nath has been instrumental in the development of COMP360.
• CMPS stock has shown resilience despite broader market selloffs.
• Clinical trials for COMP360 have been successful, pointing to a potential 2027 market launch.